Clinical trials: Platinum Resistant Ovarian Cancer
Ovarian Cancer
Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-study screening may be done to test a sample of tissue for biomarkers to determine participation in…
- Trial name
- IPROC (NCT04918186)
- Testing
- Durvalumab, BA3011, BA3021
- Where
- 6 sites in United States, Canada
- Volunteers
- 60 people
- Sponsor
- Canadian Cancer Trials Group
Epithelial Ovarian Cancer
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
The purpose of this study is to evaluate the objective response rate, safety and identify potential biomarkers in platinum-resistant ovarian cancer patients treated with voreloxin injection given on a 28-day cycle.
- Trial name
- NCT00408603
- Testing
- Voreloxin Injection
- Where
- 20 sites in United States, Canada
- Volunteers
- 183 people
- Sponsor
- Sunesis Pharmaceuticals
Ovarian Cancer
Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer
The study is designed to assess the therapeutic efficacy and toxicity of the combination chemotherapy with pembrolizumab in recurrent, platinum resistant OC patients.
- Trial name
- MITO27 (NCT03539328)
- Testing
- Pembrolizumab, Gemcitabine, Paclitaxel
- Where
- Italy
- Volunteers
- 138 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
This study is phase II, open label, clinical trial to determine the efficacy of Oregovomab and non-platinum chemotherapy in PARP inhibitor resistant ovarian, fallopian tube, or primary peritoneal cancer patients who were not…
- Trial name
- NCT05407584
- Testing
- Orevogomab+PLD, Orevogomab+Paclitaxel
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Yonsei University
Solid Tumors
Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer
The goal of this clinical research study is to find out if giving azacitidine with valproic acid plus carboplatin can help control advanced cancer. The safety of this treatment will be studied as well.
- Trial name
- NCT00529022
- Testing
- Azacitidine, Valproic Acid, Carboplatin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent, Platinum-resistant
"Re-Stimulated" TILs And IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is a phase I clinical study for patients with platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer, and the response to a combination of cyclophosphamide, autologous tumor-infiltrating…
- Conditions
- Recurrent, Platinum-resistant, High Grade Serous Ovarian Cancer, Fallopian Tube Cancer
- Trial name
- NCT01883297
- Testing
- Re-stimulated tumor-infiltrating lymphocytes (TILs), Interleukin-2, Cyclophosphamide
- Where
- Canada
- Volunteers
- 3 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer
A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed
This is an open-label, single-arm, two-stage, multicenter Phase II study evaluating the efficacy and safety of bevacizumab in women with platinum resistant, advanced (Stage III or IV) EOC (epithelial ovarian cancer) or PPC…
- Trial name
- NCT00097019
- Testing
- bevacizumab
- Volunteers
- 53 people
- Sponsor
- Genentech, Inc.
Ovarian Cancer, Peritoneal Cancer
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
The purpose of this study is to determine the safest and maximum tolerated dosing regimens for intraperitoneal oxaliplatin with intravenous docetaxel and intravenous oxaliplatin with intraperitoneal docetaxel for recurrent…
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00692900
- Testing
- intravenous docetaxel with intraperitoneal oxaliplatin, intravenous oxaliplatin with intraperitoneal docetaxel
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Pittsburgh
Solid Tumor, Advanced Solid Tumor
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
The goal of the Monotherapy Dose Escalation phase (Part 1) of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor
- Trial name
- NCT06586957
- Testing
- NKT3964, Paclitaxel, Doxorubicin
- Where
- 20 sites in United States, South Korea
- Volunteers
- 238 people
- Sponsor
- NiKang Therapeutics, Inc.
Ovarian Cancer
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
This study was designed to evaluate the effect of two dose levels of NUC-1031 (500 mg/m2 and 750mg/m2) in patients with ovarian cancer.
- Trial name
- NCT03146663
- Testing
- NUC-1031 500 mg, NUC-1031 750mg
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 53 people
- Sponsor
- NuCana plc
Ovarian Cancer
AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer
This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with…
- Trial name
- NCT00976911
- Testing
- Bevacizumab, liposomal doxorubicin, paclitaxel
- Where
- 117 sites in Belgium, Bosnia and Herzegovina and 12 more
- Volunteers
- 361 people
- Sponsor
- Hoffmann-La Roche
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Ovarian Neoplasms
TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer
The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) populations.
- Trial name
- NCT00057720
- Testing
- TLK286 HCl for injection, topotecan hydrochloride for injection, doxorubicin HCl liposome injection
- Where
- 320 sites in United States, Argentina and 11 more
- Volunteers
- 440 people
- Sponsor
- Telik
Ovarian Neoplasms, Primary Peritoneal Cancer
Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy
The purposes of this study are to determine: - whether standard or higher doses of pemetrexed should be given to patients with ovarian or primary peritoneal cancer that has recurred; - the safety and side effects of standard and…
- Trial name
- NCT00109096
- Testing
- Pemetrexed
- Where
- 21 sites in Belgium, Germany and 2 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer
This is a Phase 1a/1b study of SC-003 as a single agent and in combination with ABBV-181 in patients with platinum-resistant/refractory ovarian cancer.
- Trial name
- NCT02539719
- Testing
- SC-003, SC-003 in combination with ABBV-181
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- Stemcentrx
Ovarian Cancer
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian…
- Trial name
- NCT06394492
- Testing
- SHR-A1921, Doxorubicin, Paclitaxel
- Where
- 2 sites in China
- Volunteers
- 440 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Fallopian Tube Cancer, Ovarian Cancer
TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
The purpose of this study is to determine if treatment with paclitaxel plus AMG 386 is superior to paclitaxel plus placebo in women with recurrent partially platinum sensitive or resistant epithelial ovarian cancer, primary…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
- Trial name
- NCT01204749
- Testing
- AMG 386, Paclitaxel
- Where
- 225 sites in United States, Australia and 30 more
- Volunteers
- 919 people
- Sponsor
- Amgen
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as pemetrexed disodium, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00087087
- Testing
- pemetrexed disodium
- Where
- 35 sites in United States
- Volunteers
- 51 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Primary Peritoneal Cavity Cancer
Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006028
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 31 sites in United States, Norway
- Sponsor
- Gynecologic Oncology Group
Efficacy and Safety
Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
Ovarian cancer is the leading cause of death from gynecologic tumors in the western world. Most patients have relapses, and responses to subsequent therapies are generally short-lived.
- Trial name
- NCT04518501
- Testing
- Arsenic trioxide Tablet +Fuzuloparib Capsules
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Xing Xie